Induced Pluripotent Stem Cell (iPSC) Market Share, Size, Trends, Industry Analysis Report, By Derived Cell (Hepatocytes, Fibroblasts, Neural Cells, Amniotic Cells, Cardiomyocytes, Others); By Workflow; By Application; By Region; Segment Forecast, 2024 - 2032
- Published Date:May-2024
- Pages: 118
- Format: PDF
- Report ID: PM2014
- Base Year: 2023
- Historical Data: 2019-2022
Report Outlook
Induced Pluripotent Stem Cell (iPSC) market size was valued at USD 1,940.39 million in 2023. The market is anticipated to grow from USD 2,119.68 million in 2024 to USD 4,355.56 million by 2032, exhibiting the CAGR of 9.4% during the forecast period.
Industry Trends
The iPSC market is experiencing growth owing to the rising cases of chronic diseases, increasing geriatric population, and advancements in research and development. The market is attracting significant investments from pharmaceutical companies across the globe for advanced drug development and testing and this is catering to overall iPSC market growth.
The overall stem cell workflow is complex in nature and to many new entrants is a major hurdle for actual production of iPSC. Some of these complex processes include generation and reprogramming of iPSC and then differentiation of them into various desired cell types is a significant task that takes both expertise and resources. This trend has resulted in a rising inclination towards outsource programming as well as opting of commercial iPSC-derived cell purchase.
 Market Analysis.png)
To Understand More About this Research:Request a Free Sample Report
New entrants therefore have a host of options with regards to market entry. Several trends observed with respect to this scenario include taking concentrated efforts on reprogramming and achieving in-house differentiation, purchase of iPSC derived cell types from off-the-shelf product portfolio, or to enter into agreements with third party purveyors to produce customized models. This has spurred a range of possibilities that will feature iPSC based models for a host of disease models, phenotypic assays, and toxicology testing.
Many companies have developed transfection kits, reprogramming vectors, differentiation media, live staining kits, immunocytochemistry, among others to aid smooth workflow of iPSC production. However, it has been observed in the recent past that the demand for cells for screening and other purposes is significant and that there are significant challenges that pose significant hurdle in large scale iPSC production and differentiation.
Key Takeaways
- North America dominated the market and contributed over 35% market share of the iPSC market size in 2023
- By derived cell category, the cardiomyocytes segment dominated the global iPSC market size in 2023
- By application category, the regenerative medicine segment is projected to grow with a significant CAGR over the iPSC market forecast period
What are the market drivers driving the demand for market?
Increasing demand for body reconstruction procedures and tissue engineering
Major challenge in the field of tissue engineering is identifying novel cellular technologies that accurately mimics and reflects human physiology. Evolution of scaffold technology to address this challenge is observed to have great success rate in recent years and is expected to drive with assured growth over the forecast period.
Lack of insufficient organ donor is one of the high impacts rendering factor to drive demand for scaffold technology. Application of biomimetic tissue constructs to reproduce 3D organotypic structure has convinced large number of research entities to adopt scaffold technology for organoid generation in order to enhance transplantation procedures.
Scaffold technologies have shown potential in fulfilling the purpose of tissues engineering to restore and maintain the function of damaged organs. Increase in demand for in vitro tissue constructs that provide co-ordination of multiple cellular processes such as transportation of nutrients, mechanical stability, is expected to drive the progress of scaffold technology market. In order to accomplish proper transplantation procedures, researchers have invested efforts for development of scaffolds as matrices/support for proper insertion of the tissue substitutes in the patient’s body, which is expected to fuel growth over the forecast period.
Which factor is restraining the demand for the market?
Ethical Concerns Pertaining to Animals
Ethical concerns surrounding the use of animals, particularly bovine fetuses, in cell culture processes have emerged as a significant issue within the Induced Pluripotent Stem Cell (iPSC) market. The reliance on bovine fetal serum for cell culture poses ethical dilemmas due to the intense suffering inflicted on the animals during the blood collection process. The inhumanity of extracting blood from the fetus's heart without anesthesia has raised ethical alarms among scientists and manufacturers alike, prompting calls for alternative and more humane sourcing methods.
The heightened awareness of these ethical concerns has catalyzed regulatory actions and government interventions aimed at controlling the use of animal-derived products in cell culture. Governments, including the U.S., have implemented stringent regulations to address the ethical implications of using living organisms in research and commercial applications.
Report Segmentation
The market is primarily segmented based on derived cell, workflow, application, and region.
|
By Derived Cell |
By Workflow |
By Application |
By Region |
|
|
|
|
To Understand the Scope of this Report:Speak to Analyst
Category Wise Insights
By Derived Cell Insights
Based on derived cell category analysis, the market has been segmented on the basis of hepatocytes, fibroblasts, neural cells, amniotic cells, cardiomyocytes, and others. In 2023, the cardiomyocytes has emerged as the dominant segment in the global market since cardiomyocytes are the specialized muscle cells of the heart responsible for its contraction and pumping action. They are crucial for maintaining cardiac function and in the context of cardiovascular diseases (CVDs). With the increasing prevalence of CVDs globally, there's a growing demand for innovative therapies targeting cardiomyocytes to address various heart conditions.
The induced pluripotent stem cell (iPSC) market is witnessing a surge in demand for cardiomyocytes due to their potential in regenerative medicine. iPSC technology allows the generation of patient-specific cardiomyocytes, offering personalized treatment options for heart diseases. Collaborations between companies are accelerating this demand by pooling resources, expertise, and technologies to advance research and development in cardiomyocyte-based therapies. For instance, In June 2021, Novo Nordisk A/S unveiled a worldwide partnership with Heartseed Inc., a Japanese iPSC-producing startup. This collaboration focuses on the development, production, and marketing of HS-001, purified cardiomyocytes sourced from iPSCs, as an investigational cell therapy for heart failure.
By Application Insights
Based on application category analysis, the market has been segmented on the basis of manufacturing, academic research, drug development & discovery, toxicity screening, and regenerative medicine. The regenerative medicine segment is anticipated to witness a significant growth rate in the forecasting years. Regenerative medicine encompasses therapeutic approaches aimed at repairing, replacing, or regenerating tissues or organs to restore normal function in diseased or injured individuals. This interdisciplinary field combines principles from biology, engineering, and medicine to develop innovative treatments for a wide range of medical conditions.
Induced pluripotent stem cells (iPSCs) are a key component of regenerative medicine applications. The vast applications and robust product pipelines by companies in regenerative medicine drive the demand for iPSCs. Pharmaceutical and biotechnology companies invest heavily in iPSC research to develop novel therapeutics for various diseases, including neurological disorders, cardiovascular diseases, and degenerative conditions. For instance, in April 2022, Editas Medicine presented preclinical data on modified iPSC-derived NK cells with enhanced tumor-killing capacity, potentially improving anti-tumor activity against solid tumors. iPSC-based products hold immense potential for addressing unmet medical needs and revolutionizing patient care.
Regional Insights
North America
North America accounted for the largest revenue share in the global market. North America, region is mainly renowned for its biomedical research and innovation. Organizations such as universities, research institutions including Center for iPS Cell Research and Application (CiRA), Kyoto University, Centre for Regenerative Medicine “Stefano Ferrari” – University of Modena and Reggio Emilia, Black Family Stem Cell Institute, and biotech companies in the region are actively involved in iPSC research, leading to advancements in technology and applications.
Moreover, iPSCs are considered a novel solution for combating chronic diseases among children and adults. Owing to the growing cases of chronic illnesses such as cardiovascular diseases, cancer, and diabetes, an efficient diagnostics treatment process is needed, which is ultimately promoting the demand for the iPSCs market. Further, iPSCs offer the potential for tissue regeneration, and personalized therapeutic options to individuals for treating genetic disorders are expected to further fuel the demand during the forecast period.
Asia Pacific
The Asia Pacific market is anticipated to exhibit the highest CAGR over the forecasting years. Asia Pacific region is experiencing an increase in the demand for IPSC owing to key driving factors, including an aging population, increasing disposable income, and government efforts, among others. With respect to other regions, the Asia Pacific region is also experiencing a surge in population coupled with rising numbers of adult populations. For instance, according to published information in Global Data Plc, the total population of China in the year 2021 was 1,415.9 accounting to be 48.8% female and 51.2% male. Consequently, it is accounted that around 10% of the total population will be above the age of 65 years by 2025. Moreover, with the growing numbers of adults who are more susceptible to chronic and cardiovascular diseases owing to the sedimentary lifestyle. Additionally, the contribution of government and individual players to promote the research and development of stem cell therapy in countries such as China and India are further promoting the market growth of iPSC.
Competitive Landscape
Key market players in the iPSC market employ diverse sourcing strategies. These encompass in-house differentiation protocols, collaboration with research institutions for cell acquisition, and outsourcing to specialized iPSC suppliers. These strategies aim to ensure a consistent and high-quality supply of iPSCs for various research and therapeutic applications. The companies in the market form strategic partnerships and collaborations with research institutions, biotech firms, and healthcare companies to accelerate innovation. For instance, in June 2022, Fate Therapeutics, Inc. announced that it will collaborate with ONO Pharmaceutical Co., Ltd. (ONO) to develop chimeric antigen receptor (CAR) NK cell collaboration candidates as part of its off-the-shelf, iPSC-derived, cell-based cancer immunotherapy program.
Some of the major players operating in the global market include:
- Astellas Pharma Inc.
- Axol Bioscience Ltd.
- Cynata Therapeutics Limited
- Fate Therapeutics
- FUJIFILM Holdings Corporation (Cellular Dynamics)
- Ncardia
- REPROCELL Inc.
- Takara Bio Inc.
- Thermo Fisher Scientific Inc.
- ViaCyte, Inc
Recent Developments
- In June 2023, FUJIFILM Cellular Dynamics has launched its iCell Blood-Brain Barrier Isogenic Kit for scientists who are involved in the research and development of neuroactive drugs. This kit is made using human induced pluripotent stem cells (iPSC).
- In April 2022, Ncardia launched a new business called CellisticTM to focus on the development and manufacturing of iPSC-based cell therapies. Leveraging its established iPSC differentiation and expansion expertise, Ncardia aims to provide robust cell-specific manufacturing platforms to address the growing need for advanced iPSC cell therapy solutions.
- In June 2021, REPROCELL has opened a new Seed iPSC Manufacture Suite (SiMS) in response to increasing demand for iPSC-derived Master Cell Banks (MCBs)
- In June 2022, Fate Therapeutics, Inc. announced that it will collaborate with ONO Pharmaceutical Co., Ltd. (ONO) to develop chimeric antigen receptor (CAR) NK cell collaboration candidates as part of its off-the-shelf, iPSC-derived, cell-based cancer immunotherapy program. This collaboration will aim to leverage the potential of CAR-NK cell therapies in the treatment of cancer
Report Coverage
The iPSC market report emphasizes on key regions across the globe to provide better understanding of the product to the users. Also, the report provides market insights into recent developments, trends and analyzes the technologies that are gaining traction around the globe. Furthermore, the report covers in-depth qualitative analysis pertaining to various paradigm shifts associated with the transformation of these solutions.
The report provides detailed analysis of the market while focusing on various key aspects such as competitive analysis, derived cell, workflow, application, and their futuristic growth opportunities.
iPSC Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2024 |
USD 2,119.68 million |
|
Revenue forecast in 2032 |
USD 4,355.56 million |
|
CAGR |
9.4% from 2024 – 2032 |
|
Base year |
2023 |
|
Historical data |
2019 – 2022 |
|
Forecast period |
2024 – 2032 |
|
Quantitative units |
Revenue in USD million and CAGR from 2024 to 2032 |
|
Segments covered |
By Derived Cell, By Workflow, By Application, By Region |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America; Middle East & Africa |
|
Customization |
Report customization as per your requirements with respect to countries, region and segmentation. |
FAQ's
Induced Pluripotent Stem Cell (iPSC) Market Size Worth USD 4,355.56 Million by 2032
Key players in the induced pluripotent stem cell (iPSC) market are Astellas Pharma Inc., Axol Bioscience Ltd., Cynata Therapeutics Limited, Fate Therapeutics
North America contribute notably towards the global induced pluripotent stem cell (iPSC) market.
Induced Pluripotent Stem Cell (iPSC) market exhibiting the CAGR of 9.4% during the forecast period.
The induced pluripotent stem cell (iPSC) market report covering key segments are derived cell, workflow, application, and region
